Crinetics Pharmaceuticals Stock Performance
| CRNX Stock | USD 35.07 0.87 2.42% |
The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Crinetics Pharmaceuticals will likely underperform. At this point, Crinetics Pharmaceuticals has a negative expected return of -0.65%. Please make sure to confirm Crinetics Pharmaceuticals' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Crinetics Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Crinetics Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.42) | Five Day Return 2.87 | Year To Date Return (31.97) | Ten Year Return 43.08 | All Time Return 43.08 |
1 | Disposition of 15000 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 52.09 subject to Rule 16b-3 | 01/03/2025 |
2 | Crinetics Pharmaceuticals Inc to Present at J.P. Morgan Healthcare Conference | 01/06/2025 |
3 | Disposition of 2500 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 19.64 subject to Rule 16b-3 | 01/07/2025 |
4 | Acquisition by Deardorf Caren of 12500 shares of Crinetics Pharmaceuticals at 44.71 subject to Rule 16b-3 | 01/24/2025 |
5 | On The My Stocks Page - Stock Traders Daily | 01/29/2025 |
6 | Disposition of 1035 shares by Stephen Betz of Crinetics Pharmaceuticals at 51.5 subject to Rule 16b-3 | 01/31/2025 |
7 | Disposition of 5000 shares by Pizzuti Dana of Crinetics Pharmaceuticals at .07 subject to Rule 16b-3 | 02/03/2025 |
8 | Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of CarMax, Inc. | 02/13/2025 |
9 | Disposition of 3000 shares by Stephen Betz of Crinetics Pharmaceuticals at 45.37 subject to Rule 16b-3 | 02/14/2025 |
10 | Disposition of 15000 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 16.89 subject to Rule 16b-3 | 02/21/2025 |
11 | What To Expect From Crinetics Pharmaceuticals Inc Q4 2024 Earnings | 02/26/2025 |
12 | Is Crinetics Pharmaceuticals the Worst Performing Mid Cap Stock to Buy According to Analysts | 02/27/2025 |
13 | Q4 2024 Crinetics Pharmaceuticals Inc Earnings Call Transcript | 02/28/2025 |
14 | Insider Trading | 03/05/2025 |
15 | Disposition of 350 shares by Struthers Richard Scott of Crinetics Pharmaceuticals subject to Rule 16b-3 | 03/07/2025 |
16 | Acquisition by Tobin Schilke of 52000 shares of Crinetics Pharmaceuticals subject to Rule 16b-3 | 03/10/2025 |
17 | Disposition of 875 shares by Struthers Richard Scott of Crinetics Pharmaceuticals at 34.83 subject to Rule 16b-3 | 03/19/2025 |
18 | Crinetics Pharmaceuticals, Inc. Insider Dana Pizzuti Sells 2,515 Shares | 03/21/2025 |
19 | Crinetics Pharmaceuticals Analyst Sees Around 70 percent Upside For Stock, Cites More Investor Interest In Endocrinology | 03/25/2025 |
| Begin Period Cash Flow | 56.2 M |
Crinetics |
Crinetics Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,392 in Crinetics Pharmaceuticals on December 26, 2024 and sell it today you would lose (1,885) from holding Crinetics Pharmaceuticals or give up 34.96% of portfolio value over 90 days. Crinetics Pharmaceuticals is currently does not generate positive expected returns and assumes 3.6704% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Crinetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Crinetics Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crinetics Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Crinetics Pharmaceuticals, and traders can use it to determine the average amount a Crinetics Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1758
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRNX |
Estimated Market Risk
| 3.67 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.65 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Crinetics Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crinetics Pharmaceuticals by adding Crinetics Pharmaceuticals to a well-diversified portfolio.
Crinetics Pharmaceuticals Fundamentals Growth
Crinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Crinetics Pharmaceuticals, and Crinetics Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crinetics Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (326.13) % | ||||
| Current Valuation | 2.04 B | ||||
| Shares Outstanding | 93.05 M | ||||
| Price To Earning | (12.03) X | ||||
| Price To Book | 2.52 X | ||||
| Price To Sales | 3,219 X | ||||
| Revenue | 1.04 M | ||||
| Gross Profit | (239.12 M) | ||||
| EBITDA | (338.85 M) | ||||
| Net Income | (298.41 M) | ||||
| Cash And Equivalents | 408.51 M | ||||
| Cash Per Share | 7.60 X | ||||
| Total Debt | 51.72 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.94 X | ||||
| Book Value Per Share | 14.26 X | ||||
| Cash Flow From Operations | (225.97 M) | ||||
| Earnings Per Share | (3.69) X | ||||
| Market Capitalization | 3.34 B | ||||
| Total Asset | 1.43 B | ||||
| Retained Earnings | (952.11 M) | ||||
| Working Capital | 1.32 B | ||||
| Current Asset | 44.96 M | ||||
| Current Liabilities | 2.41 M | ||||
About Crinetics Pharmaceuticals Performance
Evaluating Crinetics Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Crinetics Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Crinetics Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.1 K | 2.2 K | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.23) | (0.21) |
Things to note about Crinetics Pharmaceuticals performance evaluation
Checking the ongoing alerts about Crinetics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Crinetics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Crinetics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Crinetics Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.04 M. Net Loss for the year was (298.41 M) with loss before overhead, payroll, taxes, and interest of (239.12 M). | |
| Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (225.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6. | |
| Crinetics Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Crinetics Pharmaceuticals Analyst Sees Around 70 percent Upside For Stock, Cites More Investor Interest In Endocrinology |
- Analyzing Crinetics Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crinetics Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Crinetics Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crinetics Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crinetics Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crinetics Pharmaceuticals' stock. These opinions can provide insight into Crinetics Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.